Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Original ArticlesMaintenance Dialysis
You have accessRestricted Access

Association of Tubular Solute Clearance with Symptom Burden in Incident Peritoneal Dialysis

Ke Wang, Michelle Nguyen, Yan Chen, Andrew N. Hoofnagle, Jessica O. Becker, Leila R. Zelnick, John Kundzins, Anne Goodling, Jonathan Himmelfarb and Bryan Kestenbaum
CJASN April 2020, 15 (4) 530-538; DOI: https://doi.org/10.2215/CJN.11120919
Ke Wang
1Division of Nephrology, Department of Medicine, University of Washington, Seattle Washington;
2Division of Nephrology, Department of Medicine, University of Washington, Kidney Research Institute, Seattle, Washington;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Nguyen
2Division of Nephrology, Department of Medicine, University of Washington, Kidney Research Institute, Seattle, Washington;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yan Chen
2Division of Nephrology, Department of Medicine, University of Washington, Kidney Research Institute, Seattle, Washington;
3Department of Epidemiology, University of Washington, Seattle Washington; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew N. Hoofnagle
2Division of Nephrology, Department of Medicine, University of Washington, Kidney Research Institute, Seattle, Washington;
4Department of Laboratory Medicine, University of Washington, Seattle, Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica O. Becker
4Department of Laboratory Medicine, University of Washington, Seattle, Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leila R. Zelnick
1Division of Nephrology, Department of Medicine, University of Washington, Seattle Washington;
2Division of Nephrology, Department of Medicine, University of Washington, Kidney Research Institute, Seattle, Washington;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Leila R. Zelnick
John Kundzins
2Division of Nephrology, Department of Medicine, University of Washington, Kidney Research Institute, Seattle, Washington;
3Department of Epidemiology, University of Washington, Seattle Washington; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Goodling
2Division of Nephrology, Department of Medicine, University of Washington, Kidney Research Institute, Seattle, Washington;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Himmelfarb
1Division of Nephrology, Department of Medicine, University of Washington, Seattle Washington;
2Division of Nephrology, Department of Medicine, University of Washington, Kidney Research Institute, Seattle, Washington;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bryan Kestenbaum
1Division of Nephrology, Department of Medicine, University of Washington, Seattle Washington;
2Division of Nephrology, Department of Medicine, University of Washington, Kidney Research Institute, Seattle, Washington;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Visual Abstract

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Abstract

Background and objectives Residual kidney function is important to the health and wellbeing of patients with ESKD. We tested whether the kidney clearances of proximal tubular secretory solutes are associated with burden of uremic and heart failure symptoms among patients on peritoneal dialysis with residual kidney function.

Design, setting, participants, & measurements We enrolled 29 patients on incident peritoneal dialysis with residual urine output >250 ml daily. We used targeted liquid chromatography-mass spectrometry to quantify plasma, 24-hour urine, and peritoneal dialysate concentrations of ten tubular secretory solutes. We calculated the kidney and peritoneal dialysis clearances of each secretory solute, creatinine, and urea, and we estimated a composite kidney and peritoneal secretion score. We assessed for uremic symptoms using the Dialysis Symptom Index and heart failure–related symptoms using the Kansas City Cardiomyopathy Questionnaire. We used linear regression to determine associations of composite secretory solute clearances and GFRurea+Cr with Dialysis Symptom Index symptom score and Kansas City Cardiomyopathy Questionnaire summary score.

Results Mean residual kidney clearances of creatinine and urea were 8±5 and 9±6 ml/min per 1.73 m2, respectively, and mean GFRurea+Cr was 8±5 ml/min per 1.73 m2. The residual kidney clearances of most secretory solutes were considerably higher than creatinine and urea clearance, and also, they were higher than their respective peritoneal dialysis clearances. After adjustments for age and sex, each SD higher composite kidney secretion score was associated with an 11-point lower Dialysis Symptom Index score (95% confidence interval, −20 to −1; P=0.03) and a 12-point higher Kansas City Cardiomyopathy Questionnaire score (95% confidence interval, 0.5- to 23-point higher score; P=0.04). Composite peritoneal dialysis secretion score was not associated with either symptom assessment.

Conclusions Residual kidney clearances of secretory solutes are higher than peritoneal dialysis clearances. Kidney clearances of secretory solutes are associated with patient-reported uremic and heart failure–related symptoms.

  • proximal tubular solute clearance
  • residual kidney function
  • uremic symptoms
  • creatinine
  • renal dialysis
  • Linear Models
  • urea
  • Symptom Assessment
  • peritoneal dialysis
  • Kidney Failure
  • Chronic
  • Peritoneum
  • Dialysis Solutions
  • heart failure
  • Mass Spectrometry
  • Chromatography
  • Liquid
  • Patient Reported Outcome Measures
  • Cardiomyopathies

Introduction

Among patients receiving maintenance dialysis, the contribution of residual kidney function (RKF) toward health and wellbeing is well established. Observational studies consistently demonstrate associations of RKF with improved survival and better quality of life (1–6). The physiologic importance of RKF is highlighted by recognized limitations of currently available dialysis therapies, which cannot remove protein-bound solutes or maintain minute-to-minute electrolyte homeostasis. Consequently, estimation of RKF remains an important component of dialysis clinical care.

Current assessment of RKF is on the basis of the GFR, which can be measured by the average of creatinine and urea clearance in ESKD (7,8). However, GFR incompletely describes the multifaceted biologic functions of the kidneys. The secretion of organic solutes by the proximal tubules is a vital intrinsic kidney function that may be particularly important in ESKD because many secreted solutes are highly protein bound, preventing adequate clearance by glomerular filtration or by currently available dialysis treatments. Many solutes that are eliminated predominantly by tubular secretion are uremic toxins that accumulate and are suspected to contribute to adverse clinical outcomes (9–11). Moreover, proximal tubular secretion is an active process requiring cellular energy and coordination of numerous transporters, suggesting potential contrasts with glomerular filtration (12,13). Despite its potential importance, tubular secretory clearance is rarely estimated in ESKD.

We used a novel targeted mass spectrometric assay to measure the kidney and peritoneal clearances of tubular secretory solutes in an incident cohort of patients on peritoneal dialysis (PD). We compared residual kidney and PD clearances of secretory solutes, creatinine, and urea, and we tested whether residual clearances of these solutes were associated with the severity of uremic and heart failure symptoms.

Materials and Methods

Patient Recruitment and Data Collection

Between June 2017 and October 2018, we recruited 29 patients on incident PD from outpatient units affiliated with the Northwest Kidney Centers (Seattle, WA). Eligibility criteria included PD initiation within the previous 1 year and self-reported residual urine output >250 ml daily. Major exclusions were a history of kidney transplantation, previous hemodialysis (HD), age <18 years old, non-English speaking, and inability to provide informed consent. We further excluded persons who regularly used medications that could interfere with tubular secretion: probenecid, cimetidine, ranitidine, mycophenolate, olmesartan, indomethacin, trimethoprim-sulfamethoxazole, and procainamide. The University of Washington’s institutional review board approved the study, and all participants provided informed consent. During the visit, each patient brought in clinical collections of 24-hour urine and dialysate drainage. Clinical staff collected a blood sample, an aliquot from the 24-hour urine specimen, and an aliquot containing equal proportions (1/1000 of drainage volume) of dialysate effluent from each exchange over the preceding 24 hours. We centrifuged all blood samples immediately after collection and stored all specimens at −80°C until assay.

Measurement of Tubular Secretory Solutes

Through literature review, we initially selected a panel of secretory solutes on the basis of specificity for known proximal tubular transporters, an increase in circulating concentrations following transporter knockout in experimental models, a high reported protein binding percentage, and reported kidney clearances that substantially exceed GFR (9,10,14–18). We developed a targeted liquid chromatography-tandem mass spectrometry assay for these solutes in plasma and urine using labeled internal standards as previously described (19,20). Briefly, we extracted plasma solutes from bound proteins using protein precipitation with acidified acetonitrile and solid-phase extraction through phospholipid removal. We extracted urine solutes using solid-phase extraction using either a mixed cation exchange extraction plate or a hydrophilic-lipophilic binding extraction plate. We reconstituted dried extracts in acetonitrile/formic acid and injected solution onto a Restek PFPP chromatographic column. The column eluate was subsequently introduced into a triple quadrupole tandem mass spectrometer (Sciex 6500). To maximize the accuracy of the calibration and minimize laboratory imprecision, we used standard addition of purified analytes that were quantified using nuclear magnetic resonance to determine the concentration of the analytes in the calibrator. We performed further validation experiments to maximize precision. Inter- and intra-assay coefficients of variation for individual solutes in plasma and urine range from 3.4% to 14.7% (Supplemental Table 1).

We were unable to determine the lower limits of detection for three solutes due to isobaric interference (adipic acid, suberic acid, and succinic acid), and therefore, we excluded these solutes from further analyses. We further excluded pantothenic acid from consideration on the basis of previous studies demonstrating glomerular filtration and tubular reabsorption of this compound (21,22), and we excluded 3-hydroxy hippurate due to implausibly high kidney clearance. Subsequent protein binding studies performed in our laboratory revealed that three additional solutes (isovalerylglycine, tiglylglycine, and xanthosine) had lower binding percentages than previously reported (Supplemental Table 1). However, we retained these solutes in this study because their kidney clearances greatly exceeded GFR, suggesting tubular secretion as the major kidney pathway of elimination.

Symptom Assessment

We administered the Dialysis Symptom Index (DSI) (23) to evaluate uremic symptoms and a modified version of the Kansas City Cardiomyopathy Questionnaire (KCCQ) (24) to further elicit specific symptoms of dyspnea, fatigue, and lower-extremity swelling. The DSI queries regarding the presence and severity of 30 physical or emotional symptoms during the past week. Participants rated each symptom using a five-point severity scale. The overall DSI symptom score ranges from 0 to 150, with higher scores indicating worse symptom burden. The DSI was systemically developed and validated among patients on long-term dialysis and demonstrates good test-retest reliability and content validity in HD. The questionnaire assesses numerous symptoms that are both highly prevalent and clinically relevant in ESKD on the basis of literature review, dedicated focus groups consisting of patients and providers, and experts’ assessments (23). However, we currently know very little regarding which specific symptoms are causally related to the retention of protein-bound solutes. Therefore, we assessed the association of secretory solute clearance with overall DSI severity.

The KCCQ is a 23-item questionnaire that evaluates the severity of dyspnea, fatigue, and lower-extremity swelling and the effect of these symptoms on physical functioning and quality of life. The KCCQ was developed and validated in heart failure populations (24), and it has been modified for use in CKD (25,26). However, this instrument has not been validated in ESKD. We transformed raw KCCQ scores into a summary score ranging from 0 to 100, with higher scores indicating better overall function (24). Prior studies have suggested that a KCCQ summary score <75 indicates clinically significant symptoms (24,27,28). The KCCQ has been well validated and carries prognostic significance in patients with established heart failure and in patients with CKD but no history of heart failure (25,27,29). One participant did not complete the questionnaires and was excluded from subsequent analyses involving symptom assessment.

Measurement of Other Study Data

Study participants provided self-reported demographics and medical conditions via study questionnaires. We used the electronic medical record to ascertain active medications, modality of PD, and the clinically suspected cause of ESKD. Clinical staff measured height, weight, 24-hour urine volume, and 24-hour dialysate volume during the adequacy visit. We measured serum and urine creatinine concentrations using the modified Jaffe method and urine urea concentration using enzymatic conductivity on the Beckman Coulter DxC 600.

Calculations

We calculated the kidney and peritoneal clearances of urea, creatinine, and each secretory solute as the volume of blood that is cleared of the solute per minute (milliliters per minute):Embedded ImageEmbedded Imagewhere [x] represents the solute concentration in urine, plasma, or dialysate and V represents the urine or dialysate volume per minute over the collection period. All clearances represent total urinary clearances, which include the bound and unbound fractions. We measured GFRurea+Cr by calculating the average of urea and creatinine clearances and standardizing to 1.73 m2 body surface area (milliliters per minute per 1.73 m2) according to clinical guidelines established by the National Kidney Foundation (30). We also standardized all clearance values to the same units.

Statistical Analyses

We expressed kidney and peritoneal solute clearances as means and 95% confidence intervals (95% CI). We computed a composite score for kidney and peritoneal secretory clearance, which represents a scaled average of the ten individual secretory clearances. We first standardized log-transformed secretory clearance of each individual solute to a 0–100 scale as described below:Embedded ImageWe then determined the average of the ten standardized secretory clearances to create a composite secretion score. We used scatter plots, Pearson correlation coefficients, and linear regression to determine associations of secretory solute clearances and GFRurea+Cr with DSI and KCCQ scores. Given the small sample size, we were parsimonious in the selection of covariates: age, sex, and GFRurea+Cr. P values are presented without correction for multiple comparisons. A nominal P value of 0.05 was taken as evidence of statistical significance for regression analyses. Analyses were conducted using STATA 14 (StataCorp, College Station, TX).

Results

Description of the Study Population

Among the 29 study participants, the mean duration of PD was 4.0±2.9 months. The mean measured residual GFRurea+Cr was 8±5 ml/min per 1.73 m2 (Table 1). Mean age of the study cohort was 55±12 years old; 69% of participants were men, and 52% were white. Hypertension (96%) and diabetes (48%) were the most prevalent comorbidities. Detailed dialysis prescriptions are provided in Supplemental Table 2. Metabolic parameters of hemoglobin, bicarbonate, parathyroid hormone, and phosphorus levels were within target ranges for ESKD. The mean 24-hour ultrafiltration volume was 652±840 ml (Supplemental Table 2). Higher kidney clearances of secretory solutes, reflected by the composite secretion score, were correlated with higher residual urine volume (Rho=0.66; P=0.001) and with lower 24-hour ultrafiltration volume (Rho=−0.62; P<0.001).

View this table:
  • View inline
  • View popup
Table 1.

Participant characteristics

Comparison of Residual Kidney and PD Solute Clearances

The mean residual kidney clearances of creatinine and urea were 8±5 and 9±6 ml/min per 1.73 m2, respectively (Table 2). The kidney clearances of most secretory solutes were considerably higher than that of creatinine or urea, with the highest values observed for hippurate (mean of 95±72 ml/min per 1.73 m2) and dimethyluric acid (mean of 57±67 ml/min per 1.73 m2). In contrast, the kidney clearance of p-cresol sulfate (mean of 1±0.8 ml/min per 1.73 m2) was lower than that of creatinine and urea. With the exception of p-cresol sulfate, the kidney clearance of all other solutes exceeded GFR, with the ratio of residual secretory clearance to glomerular filtration ranging from 1.03 for indoxyl sulfate to 13.7 for hippurate. The residual kidney clearance of each secretory solute was substantially higher than its respective PD clearance, ranging up to 23-fold higher for kynurenic acid clearance. The peritoneal clearance of most secretory solutes was lower than the average of peritoneal urea and creatinine clearances. Correlations between kidney secretory clearances and GFRurea+Cr ranged from 0.38 for dimethyluric acid to 0.91 for isovalerylglycine (Supplemental Table 3). Secretory solute concentrations in urine were substantially higher compared with concentrations in dialysate and plasma (Supplemental Table 4). Composite kidney solute clearance was inversely correlated with composite peritoneal solute clearance (Supplemental Figure 1).

View this table:
  • View inline
  • View popup
Table 2.

Residual kidney and peritoneal dialysis solute clearance (n=29)

Associations of Residual Kidney and Peritoneal Solute Clearances with DSI Symptom Score

The median overall DSI symptom severity score was 25 (interquartile range [IQR], 10–44), and the median number of symptoms was 9 (IQR, 4–14). The most prevalent symptoms were muscle cramps (61%), leg swelling (59%), fatigue (57%), and difficulty with sexual arousal (57%) (Supplemental Table 5). Higher residual GFRurea+Cr and higher composite kidney solute clearance were correlated with lower DSI scores. This correlation tended to be modestly higher for composite kidney solute clearance compared with GFRurea+Cr (Figure 1, Table 3). Among the individual solutes, the residual kidney clearances of tiglylglycine, kynurenic acid, and isovalerylglycine were most strongly correlated with DSI scores. After adjustments for age and sex, each SD higher composite kidney secretion score was associated with an estimated 11-point lower DSI score (95% CI, 20- to 1-point lower; P=0.03) (Table 5). This association was similar in magnitude after adjustment for residual GFRurea+Cr. Conversely, composite peritoneal solute clearance was not associated with uremic symptom severity (Figure 1, Tables 4 and 5). In examining individual symptoms, higher kidney secretory clearance and GFR were most strongly associated with decreased appetite, leg swelling, and insomnia (Supplemental Table 6).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Kidney tubular soute clearance correlates with severity of uremic and heart failure symptoms. Scatter plots with fitted least squares regression lines are shown. Rho and P values generated from Pearson regression are shown. GFRurea+Cr is expressed in milliliters per minute per 1.73 m2. Composite secretion score is standardized on a scale of 1–100.

View this table:
  • View inline
  • View popup
Table 3.

Correlations of kidney solute clearances with symptoms (n=28)

View this table:
  • View inline
  • View popup
Table 4.

Correlations of peritoneal solute clearances with symptoms (n=28)

View this table:
  • View inline
  • View popup
Table 5.

Association of kidney solute clearances with symptoms (n=28)

Associations of Residual Secretory Clearances with KCCQ Summary Score

The median overall KCCQ score was 80 (IQR, 51–91), and 43% of participants had overall KCCQ scores <75. Higher residual GFRurea+Cr and higher residual kidney solute clearances tended to track with higher (better) KCCQ scores (Figure 1, Table 3); however, correlations were weaker than those observed for DSI scores. After adjustment for age and sex, each SD higher composite kidney secretion score was associated with an estimated 12-point higher KCCQ score (95% CI, 0.5- to 23-point higher score; P=0.04). However, this association was weakened by adjustment for residual GFRurea+Cr. Higher peritoneal solute clearance was correlated with lower KCCQ scores (Figure 1, Table 4); however, this association was not statistically significant (Table 5). Correlations of combined kidney and PD solute clearances were comparable with correlations with kidney solute clearances alone given the relatively small contribution of PD clearance toward total clearance (Supplemental Table 7).

Discussion

In a primary cohort of patients recently initiating PD, we observed substantially higher residual kidney clearances of tubular secretory solutes compared with their respective peritoneal dialytic clearances. The residual kidney clearances of most secretory solutes were also considerably higher than the clearances of creatinine and urea. Higher kidney secretory clearances but not PD clearances were correlated with a lower burden of uremic and heart failure symptoms. Taken together, our findings suggest that the residual kidney clearance of tubular secretory solutes is an important component of RKF that may hold clinical significance.

Consistent with our findings, two prior studies of PD have shown the superiority of residual kidney clearance compared with dialytic clearance in eliminating p-cresol sulfate, a small protein-bound molecule that is primarily cleared by proximal tubular secretory transport. These studies found a four-times higher residual kidney clearance of p-cresol sulfate compared with its peritoneal clearance (31,32). Similarly, among patients on HD with RKF, the fraction of p-cresol sulfate, indoxyl sulfate, and hippurate that is removed by residual kidney clearance was two to three times higher than that of urea. Higher RKF, measured by 24-hour kidney creatinine and urea clearance, was also associated with lower plasma levels of the three protein-bound solutes (33).

The relatively low PD clearance of secretory solutes likely reflects their larger size and high degree of protein binding. The peritoneal capillary membrane is the principal determinant of solute transport into the peritoneal cavity. Small and water-soluble solutes diffuse through protein-restrictive pores, which account for most of the capillary exchange membrane. Larger protein-bound solutes are carried by convection through larger pores, which exist in substantially fewer numbers (34,35). Intriguingly, we observed relatively low dialytic clearances of solutes that demonstrated a low-protein binding percentage (isovalerylglycine, tiglylglycine, and xanthosine), suggesting that laboratory assessment of protein binding on the basis of equilibrium dialysis or centrifugation may not fully correspond with the free movement of these solutes across the peritoneal membrane in uremia. Additionally, the molecular weight of the evaluated secretory solutes is 1.4–2.5 times higher than that of creatinine and 2.6–4.7 times higher than that of urea, potentially contributing to their slower dialytic clearances.

We found that the composite residual kidney clearance but not peritoneal clearance of secretory solutes is associated with lower uremic and heart failure symptom burden. The pathogenesis underlying the clinical syndrome of uremia remains unclear because only a few small studies have directly examined relationships between candidate solutes and uremic symptomology. In a study of 30 patients on incident PD, the severity of gastrointestinal and neurologic symptoms was significantly correlated with blood levels of p-cresol sulfate but not with urea or creatinine (32). Among 141 patients on maintenance HD, circulating concentrations of phenylacetylglutamine and hippurate were most strongly associated with impaired executive function (36). Furthermore, we currently know very little regarding which specific solutes of the >150 candidate uremic solutes actually exhibit clinical toxicity (14). The association between kidney clearance of secretory solutes with heart failure–related symptoms may be partially explained by improved volume control because higher kidney clearances of secretory solutes were correlated with higher 24-hour urine volume and with lower ultrafiltration volume. Our findings are an important addition to the existing literature, suggesting that the accumulation of protein-bound solutes may contribute to symptom development in ESKD and motivate future larger metabolomics studies to identify clinical consequences of individual solutes.

Our study has several strengths. We used a targeted mass spectrometry assay that was specifically developed for the secretory solutes of interest using labeled internal standards and external calibration. We calculate solute clearances using 24-hour urine and dialysate samples, which are theoretically independent of characteristics that might influence their production. We also assessed for symptom burden using well validated questionnaires. However, we are not powered to examine associations with individual symptoms. Another limitation of our study is that DSI and KCCQ scores may not be specific for uremic toxicity because the symptoms elicited by these instruments may be caused by conditions other than uremia. The KCCQ also has not been validated in patients with ESKD. Furthermore, given the known diurnal variations of plasma concentrations of secretory solutes (20), estimation of kidney clearance from a single plasma level may be prone toward error. For instance, the 24-hour clearance of a solute may be falsely high if its plasma concentration obtained on a single occasion is lower than the true average plasma value over the 24-hour collection period. Therefore, further refinements of laboratory assessments of secretory solutes may strengthen the association between solute clearance and symptoms. Despite these limitations, our results suggest a potential mechanism underlying the pathogenesis of uremic symptomology and motivate future larger studies to explore associations between tubular secretory clearance with detailed symptom assessments.

In summary, we found residual kidney clearances of tubular secretory solutes to be substantially higher than their respective peritoneal clearances among patients initiating PD. Higher residual kidney secretory clearances were associated with fewer uremic and heart failure symptoms. The inclusion of tubular secretory clearances into the assessment of RKF could enhance assessment of RKF and uniquely inform uremic toxicity. Future strategies to improve the dialytic clearance of secretory solutes may improve patient-reported symptom burden in ESKD.

Disclosures

Dr. Hoofnagle reports receiving grants from Waters, Inc. during the conduct of the study. Dr. Kestenbaum reports personal fees from Reata Pharmaceuticals outside the submitted work. Dr. Becker, Dr. Chen, Dr. Goodling, Dr. Himmelfarb, Dr. Kundzins, Dr. Nguyen, Dr. Wang, and Dr. Zelnick have nothing to disclose.

Funding

This work was supported by National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases grants R01 DK107931 (to Dr. Kestenbaum) and R01 DK 103986 (to Dr. Kestenbaum) and an unrestricted gift from the Northwest Kidney Centers (to the Kidney Research Institute). Dr. Wang is supported by the American Society of Nephrology Ben J. Lipps Research Fellowship.

Supplemental Material

This article contains the following supplemental material online at http://cjasn.asnjournals.org/lookup/suppl/doi:10.2215/CJN.11120919/-/DCSupplemental.

Supplemental Figure 1. Correlation between composite secretion scores (peritoneal versus kidney).

Supplemental Table 1. Detection limits, laboratory variability, and characteristics of candidate secretory solutes.

Supplemental Table 2. Peritoneal dialysis prescriptions for study participants.

Supplemental Table 3. Correlations of kidney and peritoneal solute clearances.

Supplemental Table 4. Solute concentrations in urine, dialysate, and plasma.

Supplemental Table 5. Dialysis Symptom Index symptom summary.

Supplemental Table 6. Correlations of kidney functions with Individual Dialysis Symptom Index symptoms.

Supplemental Table 7. Correlations of combined residual kidney and peritoneal solute clearance with symptoms.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Received September 15, 2019.
  • Accepted February 7, 2020.
  • Copyright © 2020 by the American Society of Nephrology

References

  1. ↵
    1. Bargman JM,
    2. Thorpe KE,
    3. Churchill DN
    ; CANUSA Peritoneal Dialysis Study Group: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: A reanalysis of the CANUSA study. J Am Soc Nephrol 12: 2158–2162, 2001pmid:11562415
    OpenUrlAbstract/FREE Full Text
    1. Termorshuizen F,
    2. Korevaar JC,
    3. Dekker FW,
    4. van Manen JG,
    5. Boeschoten EW,
    6. Krediet RT
    ; NECOSAD Study Group: The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD )-2. Am J Kidney Dis 41: 1293–1302, 2003pmid:12776283
    OpenUrlCrossRefPubMed
    1. Termorshuizen F,
    2. Dekker FW,
    3. van Manen JG,
    4. Korevaar JC,
    5. Boeschoten EW,
    6. Krediet RT
    ; NECOSAD Study Group: Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 15: 1061–1070, 2004pmid:15034110
    OpenUrlAbstract/FREE Full Text
    1. Shafi T,
    2. Jaar BG,
    3. Plantinga LC,
    4. Fink NE,
    5. Sadler JH,
    6. Parekh RS,
    7. Powe NR,
    8. Coresh J
    : Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: The Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Am J Kidney Dis 56: 348–358, 2010pmid:20605303
    OpenUrlCrossRefPubMed
    1. Shemin D,
    2. Bostom AG,
    3. Laliberty P,
    4. Dworkin LD
    : Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 38: 85–90, 2001pmid:11431186
    OpenUrlCrossRefPubMed
  2. ↵
    1. Wang AY,
    2. Lai KN
    : The importance of residual renal function in dialysis patients. Kidney Int 69: 1726–1732, 2006pmid:16612329
    OpenUrlCrossRefPubMed
  3. ↵
    1. van Olden RW,
    2. van Acker BA,
    3. Koomen GC,
    4. Krediet RT,
    5. Arisz L
    : Time course of inulin and creatinine clearance in the interval between two haemodialysis treatments. Nephrol Dial Transplant 10: 2274–2280, 1995pmid:8808225
    OpenUrlCrossRefPubMed
  4. ↵
    1. van Olden RW,
    2. Krediet RT,
    3. Struijk DG,
    4. Arisz L
    : Measurement of residual renal function in patients treated with continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 7: 745–750, 1996pmid:8738810
    OpenUrlAbstract
  5. ↵
    1. Sirich TL,
    2. Aronov PA,
    3. Plummer NS,
    4. Hostetter TH,
    5. Meyer TW
    : Numerous protein-bound solutes are cleared by the kidney with high efficiency. Kidney Int 84: 585–590, 2013pmid:23636170
    OpenUrlCrossRefPubMed
  6. ↵
    1. Sirich TL,
    2. Funk BA,
    3. Plummer NS,
    4. Hostetter TH,
    5. Meyer TW
    : Prominent accumulation in hemodialysis patients of solutes normally cleared by tubular secretion. J Am Soc Nephrol 25: 615–622, 2014pmid:24231664
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Sirich TL,
    2. Meyer TW,
    3. Gondouin B,
    4. Brunet P,
    5. Niwa T
    : Protein-bound molecules: A large family with a bad character. Semin Nephrol 34: 106–117, 2014pmid:24780467
    OpenUrlCrossRefPubMed
  8. ↵
    1. Wikoff WR,
    2. Nagle MA,
    3. Kouznetsova VL,
    4. Tsigelny IF,
    5. Nigam SK
    : Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1). J Proteome Res 10: 2842–2851, 2011pmid:21476605
    OpenUrlCrossRefPubMed
  9. ↵
    1. Wu W,
    2. Bush KT,
    3. Nigam SK
    : Key role for the organic anion transporters, OAT1 and OAT3, in the in vivo handling of uremic toxins and solutes. Sci Rep 7: 4939, 2017pmid:28694431
    OpenUrlCrossRefPubMed
  10. ↵
    1. Duranton F,
    2. Cohen G,
    3. De Smet R,
    4. Rodriguez M,
    5. Jankowski J,
    6. Vanholder R,
    7. Argiles A
    ; European Uremic Toxin Work Group: Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 23: 1258–1270, 2012pmid:22626821
    OpenUrlAbstract/FREE Full Text
    1. Deguchi T,
    2. Ohtsuki S,
    3. Otagiri M,
    4. Takanaga H,
    5. Asaba H,
    6. Mori S,
    7. Terasaki T
    : Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney. Kidney Int 61: 1760–1768, 2002pmid:11967025
    OpenUrlCrossRefPubMed
    1. Miyamoto Y,
    2. Watanabe H,
    3. Noguchi T,
    4. Kotani S,
    5. Nakajima M,
    6. Kadowaki D,
    7. Otagiri M,
    8. Maruyama T
    : Organic anion transporters play an important role in the uptake of p-cresyl sulfate, a uremic toxin, in the kidney. Nephrol Dial Transplant 26: 2498–2502, 2011pmid:21303967
    OpenUrlCrossRefPubMed
    1. Itoh Y,
    2. Ezawa A,
    3. Kikuchi K,
    4. Tsuruta Y,
    5. Niwa T
    : Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal Bioanal Chem 403: 1841–1850, 2012pmid:22447217
    OpenUrlCrossRefPubMed
  11. ↵
    1. Deguchi T,
    2. Takemoto M,
    3. Uehara N,
    4. Lindup WE,
    5. Suenaga A,
    6. Otagiri M
    : Renal clearance of endogenous hippurate correlates with expression levels of renal organic anion transporters in uremic rats. J Pharmacol Exp Ther 314: 932–938, 2005pmid:15879000
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Suchy-Dicey AM,
    2. Laha T,
    3. Hoofnagle A,
    4. Newitt R,
    5. Sirich TL,
    6. Meyer TW,
    7. Thummel KE,
    8. Yanez ND,
    9. Himmelfarb J,
    10. Weiss NS,
    11. Kestenbaum BR
    : Tubular Secretion in CKD. J Am Soc Nephrol 27: 2148–2155, 2016pmid:26614381
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Rivara MB,
    2. Zelnick LR,
    3. Hoofnagle AN,
    4. Newitt R,
    5. Tracy RP,
    6. Kratz M,
    7. Weigle DS,
    8. Kestenbaum BR
    : Diurnal and long-term variation in plasma concentrations and renal clearances of circulating markers of kidney proximal tubular secretion. Clin Chem 63: 915–923, 2017pmid:28188231
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Barbarat B,
    2. Podevin RA
    : Pantothenate-sodium cotransport in renal brush-border membranes. J Biol Chem 261: 14455–14460, 1986pmid:3771539
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Karnitz LM,
    2. Gross CJ,
    3. Henderson LM
    : Transport and metabolism of pantothenic acid by rat kidney. Biochim Biophys Acta 769: 486–492, 1984
    OpenUrlPubMed
  16. ↵
    1. Weisbord SD,
    2. Fried LF,
    3. Arnold RM,
    4. Rotondi AJ,
    5. Fine MJ,
    6. Levenson DJ,
    7. Switzer GE
    : Development of a symptom assessment instrument for chronic hemodialysis patients: The Dialysis Symptom Index. J Pain Symptom Manage 27: 226–240, 2004pmid:15010101
    OpenUrlCrossRefPubMed
  17. ↵
    1. Green CP,
    2. Porter CB,
    3. Bresnahan DR,
    4. Spertus JA
    : Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: A new health status measure for heart failure. J Am Coll Cardiol 35: 1245–1255, 2000pmid:10758967
    OpenUrlFREE Full Text
  18. ↵
    1. Mishra RK,
    2. Yang W,
    3. Roy J,
    4. Anderson AH,
    5. Bansal N,
    6. Chen J,
    7. DeFilippi C,
    8. Delafontaine P,
    9. Feldman HI,
    10. Kallem R,
    11. Kusek JW,
    12. Lora CM,
    13. Rosas SE,
    14. Go AS,
    15. Shlipak MG
    ; CRIC Study Investigators: Kansas city cardiomyopathy questionnaire score is associated with incident heart failure hospitalization in patients with chronic kidney disease without previously diagnosed heart failure: Chronic renal insufficiency cohort study. Circ Heart Fail 8: 702–708, 2015pmid:25985796
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Shlipak MG,
    2. Lash JP,
    3. Yang W,
    4. Teal V,
    5. Keane M,
    6. Cappola T,
    7. Keller C,
    8. Jamerson K,
    9. Kusek J,
    10. Delafontaine P,
    11. He J,
    12. Miller ER 3rd.,
    13. Schreiber M,
    14. Go AS
    ; CRIC Investigators: Symptoms characteristic of heart failure among CKD patients without diagnosed heart failure. J Card Fail 17: 17–23, 2011pmid:21187260
    OpenUrlCrossRefPubMed
  20. ↵
    1. Soto GE,
    2. Jones P,
    3. Weintraub WS,
    4. Krumholz HM,
    5. Spertus JA
    : Prognostic value of health status in patients with heart failure after acute myocardial infarction. Circulation 110: 546–551, 2004pmid:15262843
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Chan PS,
    2. Soto G,
    3. Jones PG,
    4. Nallamothu BK,
    5. Zhang Z,
    6. Weintraub WS,
    7. Spertus JA
    : Patient health status and costs in heart failure: Insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Circulation 119: 398–407, 2009pmid:19139382
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Heidenreich PA,
    2. Spertus JA,
    3. Jones PG,
    4. Weintraub WS,
    5. Rumsfeld JS,
    6. Rathore SS,
    7. Peterson ED,
    8. Masoudi FA,
    9. Krumholz HM,
    10. Havranek EP,
    11. Conard MW,
    12. Williams RE
    ; Cardiovascular Outcomes Research Consortium: Health status identifies heart failure outpatients at risk for hospitalization or death. J Am Coll Cardiol 47: 752–756, 2006pmid:16487840
    OpenUrlFREE Full Text
  23. ↵
    National Kidney Foundation: II. NKF-K/DOQI clinical practice guidelines for peritoneal dialysis adequacy: Update 2000. Am J Kidney Dis 37[Suppl 1]: S65–S136, 2001pmid:11229968
    OpenUrlCrossRefPubMed
  24. ↵
    1. Pham NM,
    2. Recht NS,
    3. Hostetter TH,
    4. Meyer TW
    : Removal of the protein-bound solutes indican and p-cresol sulfate by peritoneal dialysis. Clin J Am Soc Nephrol 3: 85–90, 2008pmid:18045861
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Bammens B,
    2. Evenepoel P,
    3. Verbeke K,
    4. Vanrenterghem Y
    : Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 64: 2238–2243, 2003pmid:14633148
    OpenUrlCrossRefPubMed
  26. ↵
    1. Marquez IO,
    2. Tambra S,
    3. Luo FY,
    4. Li Y,
    5. Plummer NS,
    6. Hostetter TH,
    7. Meyer TW
    : Contribution of residual function to removal of protein-bound solutes in hemodialysis. Clin J Am Soc Nephrol 6: 290–296, 2011pmid:21030575
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Rippe B
    : A three-pore model of peritoneal transport. Perit Dial Int 13[Suppl 2]: S35–S38, 1993pmid:18388123
    OpenUrlAbstract
  28. ↵
    1. Rippe B
    : Free water transport, small pore transport and the osmotic pressure gradient three-pore model of peritoneal transport. Nephrol Dial Transplant 23: 2147–2153, 2008pmid:18388123
    OpenUrlCrossRefPubMed
  29. ↵
    1. Kurella Tamura M,
    2. Chertow GM,
    3. Depner TA,
    4. Nissenson AR,
    5. Schiller B,
    6. Mehta RL,
    7. Liu S,
    8. Sirich TL
    ; FHN Study: Metabolic profiling of impaired cognitive function in patients receiving dialysis. J Am Soc Nephrol 27: 3780–3787, 2016pmid:27444566
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 15 (4)
Clinical Journal of the American Society of Nephrology
Vol. 15, Issue 4
April 07, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Association of Tubular Solute Clearance with Symptom Burden in Incident Peritoneal Dialysis
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Association of Tubular Solute Clearance with Symptom Burden in Incident Peritoneal Dialysis
Ke Wang, Michelle Nguyen, Yan Chen, Andrew N. Hoofnagle, Jessica O. Becker, Leila R. Zelnick, John Kundzins, Anne Goodling, Jonathan Himmelfarb, Bryan Kestenbaum
CJASN Apr 2020, 15 (4) 530-538; DOI: 10.2215/CJN.11120919

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Association of Tubular Solute Clearance with Symptom Burden in Incident Peritoneal Dialysis
Ke Wang, Michelle Nguyen, Yan Chen, Andrew N. Hoofnagle, Jessica O. Becker, Leila R. Zelnick, John Kundzins, Anne Goodling, Jonathan Himmelfarb, Bryan Kestenbaum
CJASN Apr 2020, 15 (4) 530-538; DOI: 10.2215/CJN.11120919
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosures
    • Funding
    • Supplemental Material
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

Original Articles

  • Incidence and Risk Factors for Dialysis Reinitiation among Patients with a History of Dialysis Dependency
  • Survey of Salary and Job Satisfaction of Transplant Nephrologists in the United States
  • Implications of Accumulated Cold Time for US Kidney Transplantation Offer Acceptance
Show more Original Articles

Maintenance Dialysis

  • Incidence and Risk Factors for Dialysis Reinitiation among Patients with a History of Dialysis Dependency
  • Long-Term Effect of Physical Exercise on the Risk for Hospitalization and Death in Dialysis Patients
  • Removal of Uremic Solutes from Dialysate by Activated Carbon
Show more Maintenance Dialysis

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • PubMed
  • Google Scholar

Keywords

  • proximal tubular solute clearance
  • residual kidney function
  • uremic symptoms
  • creatinine
  • renal dialysis
  • linear models
  • urea
  • Symptom Assessment
  • peritoneal dialysis
  • kidney failure
  • chronic
  • Peritoneum
  • Dialysis Solutions
  • heart failure
  • mass spectrometry
  • Chromatography
  • Liquid
  • patient reported outcome measures
  • Cardiomyopathies

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire